Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tectonic Therapeutic, Inc. - Common Stock
(NQ:
TECX
)
19.80
-0.71 (-3.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tectonic Therapeutic, Inc. - Common Stock
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
May 17, 2025
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
May 08, 2025
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference
May 07, 2025
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025
April 15, 2025
Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohort
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 20, 2025
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic to Participate in March Investor Conferences
February 20, 2025
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Announces $185 Million Private Placement
February 03, 2025
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
January 30, 2025
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
December 03, 2024
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
November 26, 2024
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
November 11, 2024
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
October 22, 2024
American Heart Association (AHA) poster to be presented on November 16, 2024
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
September 19, 2024
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic to Participate in September Investor Conferences
August 20, 2024
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
August 14, 2024
From
Tectonic Therapeutic
Via
GlobeNewswire
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
July 30, 2024
From
Tectonic Therapeutic
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.